19-396 - AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Status: open

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Stroke Prevention

Contact Us Or call (251) 445-9834

Description

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.